Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2021 | 1 |
2022 | 1 |
2024 | 0 |
Search Results
2 results
Results by year
Filters applied: . Clear all
Page 1
Venetoclax exposure-efficacy and exposure-safety relationships in patients with treatment-naïve acute myeloid leukemia who are ineligible for intensive chemotherapy.
Hematol Oncol. 2022 Apr;40(2):269-279. doi: 10.1002/hon.2964. Epub 2022 Feb 9.
Hematol Oncol. 2022.
PMID: 35043428
Free PMC article.
Clinical Trial.
Venetoclax plus low-dose cytarabine in Japanese patients with untreated acute myeloid leukaemia ineligible for intensive chemotherapy.
Yamauchi T, Yoshida C, Usuki K, Takada S, Matsumura I, Dobashi N, Miyazaki Y, Miyamoto T, Iida H, Asou N, Kuroda J, Ichikawa S, Komatsu N, Mendes W, Honda H, Okubo S, Kurokawa M, Jiang Q, Wei A, Ishizawa K.
Yamauchi T, et al.
Jpn J Clin Oncol. 2021 Aug 30;51(9):1372-1382. doi: 10.1093/jjco/hyab112.
Jpn J Clin Oncol. 2021.
PMID: 34322703
Free PMC article.
Clinical Trial.
Item in Clipboard
Cite
Cite